ECMO application of patients with Critical Corona Virus Disease 2019 and fulminant myocarditis

Xia Shi; Fulan Cen; Zhimin SU; Gendong Yang; Jinxiu LI; Cheng Feng; Ye Chen; Guoliang Zhang; Zhaoqin Wang; Yingxia Liu; Junmin Wen; Hong Gao

Return

ECMO application of patients with Critical Corona Virus Disease 2019 and fulminant myocarditis

VernacularTitle: ECMO在新型冠状病毒肺炎危重型合并暴发性心肌炎患者中的应用
Author: Xia SHI ¹ ; Fulan CEN ¹ ; Zhimin SU ¹ ; Gendong YANG ¹ ; Jinxiu LI ¹ ; Cheng FENG ¹ ; Ye CHEN ¹ ; Guoliang ZHANG ¹ ; Zhaoqin WANG ¹ ; Yingxia LIU ¹ ; Junmin WEN ² ; Hong GAO ¹
Author Information

1. Shenzhen Third People’s Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen 518112, China
2. Shenzhen Fuwai Hospital, Chinese Academy of Medical Sciences, Shenzhen 518057, China
Publication Type:Journal Article
Keywords: extracorporeal membrane oxygenation; Critical Corona Virus Disease 2019; Fulminant myocarditis
From: Chinese Journal of Experimental and Clinical Virology 2020;34(0):E006-E006
CountryChina
Language:Chinese
Abstract: Objective To evaluate the clinical experience of extracorporeal membrane oxygenation (ECMO) treatment on two cases of infection with the critical Corona Virus Disease 2019 (COVID-19) complicated by fulminant myocarditis (FM) . Methods This study selects two COVID-19 cases comorbid with fulminant myocarditis and had been treated with ECMO in Shenzhen Third People's Hospital from January 2020 to February 2020. We compare the index of inflammation, immunization, D-dimer and lactic acid before and after ECMO treatment in 24 and 96 hours, cardiopulmonary function before and after ECMO treatment in 24, 48, 72, 96 hours,. We also analyze the complications and clinical outcomes of the two cases during the ECMO treatment. Results Both patients were elderly obese men with chronic cardiopulmonary disease. Comparing the laboratory test results and imaging data of the two patients, the acute lung injury score, oxygenation index, albumin level, hypersensitive C-reactive protein, lactate and lactate dehydrogenase levels in 2 patients after ECMO treatment were improved as compared with those before ECMO treatment. Finally, case 1 died of multiple organ failure and his cardiac function continued to deteriorate, while, case 2 successfully withdrew and his cardiac function gradually improved. Conclusions For critical COVID-19 patients with fulminant myocarditis, ECMO treatment can improve pulmonary function in the short term, provide valuable time for rescuing COVID-19 patients with fulminant myocarditis.